Category Archives: Hepatitis C care & treatment

Covered California Frequently Asked Questions

For People Living with HIV and Hepatitis C and People Considering PrEP Covered California open enrollment begins today November 1, 2017 and continues through January 31, 2018. However, there may be some confusion about how the current Administration’s actions may impact your health care. The California HIV/AIDS…Read More

Enroll in Covered California plans November 1 to January 31, 2018!

Open enrollment is still on in California for three months. Despite efforts at the national level by the current administration to impede enrollment into federal ACA health plans, California has kept its enrollment open over three full months this year … from November 1, 2017 to…Read More

Covered CA Open Enrollment Social Media Day of Action

Today, November 1, 2017, starts open enrollment in Covered California health plans. The state will keep enrollment open through January 31, 2018. Despite the added length for California’s enrollment, many people may believe that enrollment ends on December 15 (as it will through the federal exchange) or is…Read More

Epclusa receives FDA approval for treating HCV in HIV/HCV co-infected persons

On August 1, 2017 the Food and Drug Administration (FDA) updated the approval for the Gilead HCV medication sofosbuvir/velpatasvir (400mg/100mg), brand name “Epclusa” to include HIV/HCV coinfection. This single tablet medication comprises sofosbuvir (SOF), a nucleotide polymerase inhibitor, and velpatasvir (VEL), an NS5A inhibitor, and is…Read More

July 28 is World Hepatitis Day: Eliminate Hepatitis

July 28, 2017 is World Hepatitis Day, one of only four disease-specific days recognized by the World Health Organization. Around the world and around the United States organizations and individuals come together on this day to raise awareness of the global burden of viral hepatitis and…Read More

Vosevi: Frequently Asked Questions

On July 18, 2017 the Food and Drug Administration (FDA) approved Gilead’s HCV medication sofosbuvir/velpatasvir/voxilaprevir (400mg/100mg/100mg), brand name “Vosevi” for the re-treatment of HCV in treatment-experienced people. This single tablet medication comprises sofosbuvir (SOF), a nucleotide polymerase inhibitor, velpatasvir (VEL), an NS5A inhibitor, and voxilaprevir (VOX),…Read More

Project Inform releases new report on safer consumption spaces in the U.S.

SAFER CONSUMPTION SPACES IN THE UNITED STATES: The time is right to unite for a national movement Click here for a PDF of the Report. Project Inform is pleased to release “Safer Consumption Spaces in the United States: Uniting for a National Movement.” This report stems…Read More